Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Capital Expenditures (2019 - 2025)

Harmony Biosciences Holdings' Capital Expenditures history spans 6 years, with the latest figure at $107000.0 for Q4 2025.

  • For Q4 2025, Capital Expenditures fell 79.14% year-over-year to $107000.0; the TTM value through Dec 2025 reached $310000.0, down 73.11%, while the annual FY2025 figure was $310000.0, 73.11% down from the prior year.
  • Capital Expenditures for Q4 2025 was $107000.0 at Harmony Biosciences Holdings, up from $71000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $632000.0 in Q2 2024 and bottomed at $3000.0 in Q3 2024.
  • The 5-year median for Capital Expenditures is $86000.0 (2022), against an average of $136000.0.
  • The largest YoY upside for Capital Expenditures was 2460.0% in 2025 against a maximum downside of 99.37% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $93000.0 in 2021, then decreased by 7.53% to $86000.0 in 2022, then grew by 24.42% to $107000.0 in 2023, then skyrocketed by 379.44% to $513000.0 in 2024, then tumbled by 79.14% to $107000.0 in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Capital Expenditures are $107000.0 (Q4 2025), $71000.0 (Q3 2025), and $4000.0 (Q2 2025).